| CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy (NCT05291156) | University of Campania Luigi Vanvitelli | 2022-07-21 |
| A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (NCT05217446) | Pfizer | 2022-07-11 |
| Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (NCT05330429) | Gilead Sciences | 2022-07-08 |
| Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (NCT05201612) | Grupo Espanol Multidisciplinario del Cancer Digestivo | 2022-07-07 |
| SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC (NCT05438108) | Huazhong University of Science and Technology | 2022-07-01 |
| A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (NCT05382442) | Akeso | 2022-06-27 |
| Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC (NCT05310643) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2022-05-05 |
| Medical Food for the Dietary Management of Metastatic Colorectal Cancer (NCT05183295) | Faeth Therapeutics | 2022-04-27 |
| Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (NCT05223673) | Institut de Recherches Internationales Servier | 2022-04-21 |
| Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer (NCT05016869) | Chinese Academy of Medical Sciences | 2022-04-12 |
| The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation (NCT05127759) | Shanghai Henlius Biotech | 2022-03-23 |
| Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan (NCT06495463) | Chang Gung Memorial Hospital | 2022-03-19 |
| Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC (NCT05004831) | Sun Yat-sen University | 2022-03-11 |
| Fruquintinib DDI Study With P-gp and BCRP Substrates (NCT05368805) | Hutchmed | 2022-03-02 |
| Pressure-enabled Delivery in Radioembolization (TriNav Study) (NCT05128032) | Massachusetts General Hospital | 2022-03-01 |
| A Study of ES104 in Patients With Metastatic Colorectal Cancer (NCT05167448) | Elpiscience (Suzhou) Biopharma, Ltd. | 2022-02-25 |
| A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer (NCT05130021) | Maxinovel Pty., Ltd. | 2022-01-31 |
| FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM (NCT03678428) | Sun Yat-sen University | 2021-12-31 |
| Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (NCT05007132) | Dominik Paul Modest | 2021-12-17 |
| A Screening Study Targeting Tumor-specific Antigens (NCT05158621) | Gritstone bio, Inc. | 2021-12-14 |
| Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC) (NCT04926376) | ABK Biomedical | 2021-11-02 |
| Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases (NCT05103020) | Yonsei University | 2021-11-01 |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (NCT04929223) | Hoffmann-La Roche | 2021-10-22 |
| Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer (NCT05266820) | Fujian Cancer Hospital | 2021-10-01 |
| A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (NCT05039177) | Erasca, Inc. | 2021-09-20 |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (NCT05004350) | Pierre Fabre Medicament | 2021-09-14 |
| A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer (NCT05093907) | BeyondBio Inc. | 2021-08-31 |
| The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) (NCT04948034) | Fudan University | 2021-08-23 |
| Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer (NCT05004441) | Zhou Fuxiang | 2021-07-22 |
| Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer (NCT05023720) | Henan Cancer Hospital | 2021-07-20 |
| RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins. (NCT04920422) | Bayer | 2021-07-15 |
| Immunotherapy for Third Line Metastatic Colorectal Cancer (NCT04444622) | Mirror Biologics, Inc. | 2021-07-12 |
| A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece (NCT04965870) | Hellenic Study Group of Psychoneuroimmunology in Cancer | 2021-06-30 |
| A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations (NCT04854434) | Karyopharm Therapeutics Inc | 2021-06-29 |
| Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (NCT04793958) | Mirati Therapeutics Inc. | 2021-06-24 |
| Centralized Tumour Board and Secondary Intervention Rate in mCRC (NCT04852250) | Ludwig-Maximilians - University of Munich | 2021-06-01 |
| An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (NCT04660812) | Arcus Biosciences, Inc. | 2021-05-10 |
| Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (NCT04776655) | Azienda USL Reggio Emilia - IRCCS | 2021-04-30 |
| Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study (NCT04831528) | Fudan University | 2021-04-10 |
| A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) (NCT04547166) | Shanghai Henlius Biotech | 2021-03-10 |
| Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet (NCT04898842) | Royal Surrey County Hospital NHS Foundation Trust | 2021-03-02 |
| A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (NCT06749015) | Fudan University | 2021-03-01 |
| Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients (NCT04753203) | Korean Cancer Study Group | 2021-02-28 |
| Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer (NCT04194359) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-02-04 |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068) | Artios Pharma Ltd | 2021-01-27 |
| EORTC-endorsed, Prospective European Multicenter Imaging Survey and Protocol (NCT04656782) | Ludwig-Maximilians - University of Munich | 2021-01-26 |
| 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. (NCT04689347) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2021-01-01 |
| Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study (NCT06202417) | Fudan University | 2021-01-01 |
| Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC (NCT04835142) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2020-12-31 |
| Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer (NCT04466254) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2020-12-07 |
| Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (NCT04450836) | UNICANCER | 2020-11-23 |
| Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (NCT04587128) | University of Wisconsin, Madison | 2020-10-19 |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (NCT04659382) | Federation Francophone de Cancerologie Digestive | 2020-10-07 |
| Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (NCT04108481) | University of Iowa | 2020-10-05 |
| FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer (NCT04430985) | Dorte Nielsen | 2020-09-30 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer (NCT04479436) | Daiichi Sankyo | 2020-09-14 |
| lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Patients (NCT04735900) | University Hospital, Antwerp | 2020-09-14 |
| Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) (NCT04456699) | Merck Sharp & Dohme LLC | 2020-08-19 |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (NCT04322539) | Hutchison Medipharma Limited | 2020-08-12 |
| VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (NCT04166383) | National Cancer Institute (NCI) | 2020-08-09 |
| Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects (NCT05110118) | Shandong Boan Biotechnology Co., Ltd | 2020-08-04 |
| Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial (NCT04475159) | Prof. Aviram Nissan | 2020-08-01 |
| Metastatic Colorectal Cancer. Real-World Data Analysis. (NCT04757311) | Istanbul Medeniyet University | 2020-08-01 |
| MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (NCT04495621) | Menarini Group | 2020-07-20 |
| Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR (NCT03940131) | King Abdullah Medical City | 2020-06-10 |
| LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy (NCT04166604) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2020-05-20 |
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI (NCT04247256) | Scandion Oncology A/S | 2020-05-14 |
| Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer (NCT04397601) | National Cancer Institute, Naples | 2020-05-11 |
| A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (NCT04317599) | Pierre Fabre Medicament | 2020-04-12 |
| AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (NCT04513951) | Gruppo Oncologico del Nord-Ovest | 2020-04-01 |
| Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate (NCT04126655) | Vastra Gotaland Region | 2020-02-05 |
| Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC (NCT04224415) | Yuhong Li | 2020-01-31 |
| A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (NCT04188145) | Centre Hospitalier Universitaire Dijon | 2020-01-27 |
| QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety (NCT04233151) | Qilu Pharmaceutical Co., Ltd. | 2020-01-20 |
| Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer (NCT06221423) | Fudan University | 2020-01-01 |
| Early Detection of Relapses in Stage IV Colorectal Cancer Patients (NCT04232891) | Fondazione del Piemonte per l'Oncologia | 2019-11-18 |
| BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (NCT03791398) | Brown University | 2019-11-15 |
| CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC (NCT04097444) | Chugai Pharmaceutical | 2019-10-11 |
| A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (NCT04008030) | Bristol-Myers Squibb | 2019-08-05 |
| Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (NCT04046445) | Amal Therapeutics | 2019-07-22 |
| Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer (NCT04008511) | China Medical University, China | 2019-07-01 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation (NCT03829410) | Cardiff Oncology | 2019-06-24 |
| QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (NCT03828227) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2019-06-14 |
| Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (NCT03785210) | National Cancer Institute (NCI) | 2019-06-05 |
| Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients (NCT03626922) | NSABP Foundation Inc | 2019-05-15 |
| Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (NCT03828799) | Institut du Cancer de Montpellier - Val d'Aurelle | 2019-05-14 |
| Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer (NCT03977090) | Genor Biopharma Co., Ltd. | 2019-04-04 |
| Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. (NCT03688230) | SFJ Pharmaceuticals X, LTD. | 2019-04-01 |
| iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer (NCT03867799) | Royal Marsden NHS Foundation Trust | 2019-03-27 |
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (NCT03832621) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-03-25 |
| Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (NCT03869892) | Institut de Recherches Internationales Servier | 2019-03-21 |
| Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective (NCT03935763) | Servier Affaires Médicales | 2019-03-08 |
| Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis (NCT03927898) | Chinese Academy of Medical Sciences | 2019-03-01 |
| Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer (NCT03892096) | Cadex Genomics | 2019-03-01 |
| Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer (NCT03880877) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2019-02-26 |
| Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients (NCT03829852) | Taipei Veterans General Hospital, Taiwan | 2019-02-11 |
| Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer (NCT03142282) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-01-01 |
| Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (NCT03323424) | Institut de Cancérologie de la Loire | 2019-01-01 |
| The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal Cancer (NCT04230018) | Sun Yat-sen University | 2018-12-28 |